All News
Best of 2022: Approach to ILD in Myositis Syndromes
Mehta et al have published a full read review of managing interstitial lung disease (ILD) in patients with inflammatory myopathies, a heterogeneous group of syndromes connected by ILD and and increased morbidity and mortality risk.
Read Article
CXCL5 Therapy in Lupus?
EurekAlert!
A new study has shown that restoring the balance of a protein in blood may be a promising treatment option for systemic lupus erythematosus.
Read Article
From the Hopkins Lupus cohort - Just one month of Prednisone 40 mg/d yields a FOUR fold increase in avascular necrosis risk #UTSWSLE2022 https://t.co/Kae2PMVgl7 https://t.co/XuhbkBwlCw
Links:
Dr. John Cush RheumNow ( View Tweet)
Practical Guidance for the Clinical Rheumatologist in Unplanned Pregnancies
Women of reproductive age comprise an overwhelming majority of patients with rheumatic and musculoskeletal disease.
https://t.co/x44GTLRtnT https://t.co/YlLgqeDRgP
Links:
Dr. John Cush RheumNow ( View Tweet)
73-87% of autoimmune (RA, SLE, UCTD, APL) pts used HCQ during pregnancy. HCQ significantly reduced pre-eclampsia (20% vs 9%), early-onset pre-eclampsia (8% vs 2.5%), 2nd/3rd trimester pregnancy loss (3% vs. 0.6%) https://t.co/CF5ivHeCmY https://t.co/CYqaCCuZJz
Links:
Dr. John Cush RheumNow ( View Tweet)
Review of the Rheumatic causes of Pericarditis and their management. Causes: SLE, RA, MCTD, Myositis, EGPA, GPA, IgG4-rel Dz, FMF, TRAPS, CAPS, AOSD, JIA, Sarcoidosis, Kawasakis, GCA, Takayasu's https://t.co/MQmkUe4Yey https://t.co/FSfrznoeBe
Dr. John Cush RheumNow ( View Tweet)
Lupus Research Alliance announced 2022 Distinguished Innovator Award recipients:
- Hongbo Chi, PhD, Exploring Metabolism of Follicular Helper T Cells & Lupus Progression
- Joseph Craft, MD: Processes Enabling T Cells to Be Destructive in Lupus Nephritis
https://t.co/yI2NlCHaBi https://t.co/fevBTkaxCY
Links:
Dr. John Cush RheumNow ( View Tweet)
Practical Guidance for the Clinical Rheumatologist in Unplanned Pregnancies
Women of reproductive age comprise an overwhelming majority of patients with rheumatic and musculoskeletal disease.
https://t.co/45ABQ0e2Qy https://t.co/dhLqzjf9uL
Links:
Dr. John Cush RheumNow ( View Tweet)
From a cohort of 689 SLE pts, prevalence of lupus pericarditis was 16.4% Pericarditis was signif assoc w/ renal dz (p 0.003), lymphopenia (p <.0001), thrombocytopenia (p 0.004), +APL Abs (p = 0.002) https://t.co/BndDu21aXF https://t.co/Umbq3rsF1y
Links:
Dr. John Cush RheumNow ( View Tweet)
Review of the Rheumatic causes of Pericarditis and their management. Causes: SLE, RA, MCTD, Myositis, EGPA, GPA, IgG4-rel Dz, FMF, TRAPS, CAPS, AOSD, JIA, Sarcoidosis, Kawasakis, GCA, Takayasu's https://t.co/h6zpTOIuyu https://t.co/Gy3Eaqz8sM
Links:
Dr. John Cush RheumNow ( View Tweet)
Study 119 SLE pts w/ SLEDAI-2K of 13.5 @Dx & 2.8 @ 1st birth. Half had 1+ flares at mean of 9 mos after birth. Pts in remission had less flares (37% vs 61%; p=0.008). SLE flares during pregnancy had more flares in F/U (76% vs 47%; p=0.019) https://t.co/3u3agu9wDj https://t.co/twj4YYclRz
Links:
Dr. John Cush RheumNow ( View Tweet)
Tight control of proteinuria in newly diagnosed lupus nephritis
The last 3 years have been exciting times in the field of lupus nephritis (LN) with two new licensed therapies, belimumab (BAFF-inhibitor) and voclosporin (calcineurin-inhibitor).
https://t.co/InkX6I7qUm https://t.co/U1M1DtF8Id
Links:
Dr. John Cush RheumNow ( View Tweet)
Inadequate Dosing of Hydroxychloroquine Leads to Hospitalizations in SLE
https://t.co/ZktIKo1eVl https://t.co/dtxVXZFXpk
Links:
Dr. John Cush RheumNow ( View Tweet)
Review of 120 pts w/ Catastrophic antiphospholipid syndrome showed that 54% had skin involvement & was 1st APS sx in 35%. Findings: livedo racemosa (45%), necrosis/ulcers (42%), splinter hemorrhages (29%), distal edema (23%), purpura (14%). https://t.co/HsVWlebfL2 https://t.co/dixoeHNkFQ
Links:
Dr. John Cush RheumNow ( View Tweet)
SLE preg delivery hospitalizations (77560) was associated with increased risk of CV complications, including preeclampsia [aOR 2.12] , peripartum cardiomyopathy (4.42), CHF (4), arrhythmias (2.2), AKI (7.7), stroke (4.8), VTE (6.9) w/ incr hosp costs https://t.co/PF6P8oDWZB https://t.co/jA2pHcciB1
Links:
Dr. John Cush RheumNow ( View Tweet)
SLE: Variability in Racial Disparities in Pregnancy Outcomes
Significant disparities exist in pregnancy outcomes in women with SLE, w/previous cohorts identifying Black women as having a higher risk of maternal mortality compared to White women w/SLE.
https://t.co/1PrJYpMcHx https://t.co/YN7K0Gf5Jl
Links:
Dr. John Cush RheumNow ( View Tweet)
Lupus Linked With Greater Risk of Cardiovascular Complications of Childbirth
Pregnant women with SLE were more prone to cardiovascular complications during delivery, and their risk seems to have increased over the past 15 years, according to data.
https://t.co/mRUOVrKbt2 https://t.co/m18DWxSV20
Links:
Dr. John Cush RheumNow ( View Tweet)
Study of 294 SLE pts on HCQ (2005-2021): 37 (13%) developed CHF w/ low EF (HFrEF), arrhythmia or cardiac death. After adjustments, wt-based dosing of HCQ not assoc w/ cardiac events(sHR 0.62; 0.41,0.92) & may decrease risk in non-smokers https://t.co/11dneH04bv https://t.co/pp0ELe5mqV
Links:
Dr. John Cush RheumNow ( View Tweet)
Follow us on LinkedIn too!
https://t.co/iylzzYRVAB https://t.co/7rKQShIzs5
Links:
Dr. John Cush RheumNow ( View Tweet)
Dual target blockade may be better than one in SLE
Inhibition of B-cell Activating Factor (BAFF) has revolutionised the treatment of patients with systemic lupus erythematosus (SLE).
https://t.co/uu6ygb4l8B https://t.co/nLO3oSiEVa
Links:
Dr. John Cush RheumNow ( View Tweet)
